Glenn Dranoff

Oncology

44 Binney St
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K + Supramolecular Attack Particles.

Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K + Supramolecular Attack Particles.

Journal: bioRxiv : the preprint server for biology

Published: July 03, 2026

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 26, 2026

Plasticity of tumor cell immunogenicity: is it druggable?

Plasticity of tumor cell immunogenicity: is it druggable?

Journal: Journal for immunotherapy of cancer

Published: April 14, 2025

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

Journal: Cancer cell

Published: March 20, 2025

A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma.

A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma.

Journal: Leukemia & lymphoma

Published: July 22, 2024

A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction.

A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction.

Journal: Science (New York, N.Y.)

Published: July 04, 2024

First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell-Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma.

First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell-Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma.

Journal: Cancer immunology research

Published: April 12, 2024

Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma.

Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma.

Journal: Frontiers in oncology

Published: March 04, 2024

Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer.

Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer.

Journal: Cancer research communications

Published: December 01, 2023

Granulocyte-Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade.

Granulocyte-Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade.

Journal: Cancer immunology research

Published: September 08, 2022

Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.

Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.

Journal: Cell chemical biology

Published: June 11, 2022

Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.

Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.

Journal: Cancer immunology research

Published: April 14, 2022

Showing 1-12 of 111

Last Updated: 09/26/2026